Immutep Limited (ASX: IMM)
Globally active biotechnology company Immutep Limited (ASX: IMM) has announced the grant of patent number 2601961 entitled âCompositions comprising LAG-3 and therapeutic antibodies and their uses in treating cancerâ by the European Patent Office. Following this news, the shares of IMM increased by 2.778 percent as on 29 November 2018.
This new patent is focused on the use of Immutepâs lead product candidate eftilagimod alpha in combination with a therapeutic antibody that kills tumor cells through antibody dependent cell-mediated cytotoxicity (ADCC) for the treatment of cancer. The new patent is pointing to the broad potential of efti as an immunostimulant and provides patent protection in Europe for an additional range of combination therapies. The expiry date of the patent is 3 October 2028.
On 28 November 2018, the company also announced the grant of a new patent i.e., number 3242678 which entitled âCombined Preparations for the Treatment of Cancer or Infectionâ and covering the combination of active ingredients being evaluated in the Companyâs TACTI-mel, TACTI-002, and INSIGHT-004 clinical trials. The patent is going to expire on 8 January 2036.
In the last six months, the share price of IMM increased by 16.13 percent as on 28 November 2018. IMM shares traded at $0.037 with a market capitalization of circa $111.04 million as on 29 November 2018.
Biotron Limited (ASX: BIT)
Biotron Limitedâs (ASX: BIT) shares fell by 15.625 percent on 29 November 2018 after the company released a presentation of BIT225-009 HIV-1 Phase 2 Data. Biotron Limited is focused on the design and development of a new class of antiviral drugs targeting viral? encoded viroporin proteins.
BIT225 is an HIV-1 Vpu inhibitor that targets virus assembly and is most effective in cells of monocyte lineage. The Phase 2 trial was designed to investigate whether BIT225 provides additional virological or immunological benefits on top of that seen with antiretroviral therapy (ART) Atripla in subjects commencing ART. According to the phase 2 clinical trial results BIT225 is having a unique effect, over and above viral suppression was seen with ART, further, the sCD163 result suggests a potential role of BIT225 for treatment of high-risk patients.
In FY 2018, the company reported an operating loss before financing income of $1.61mn and the basic and diluted loss per share of 0.40 cents. At the end of FY 2018, the company was having total current assets of $1.601 million.
As at 30 September 2018, the net cash used in operating activities was $0.6 million. At the end of the September quarter, the company was having Cash and cash equivalents of $0.896 million.
In the last six months, the share price of the company increased by 627.27 percent as on 28 November 2018. BITâs shares traded at $0.135 with a market capitalization of about $87.42 million as on 29 November 2018.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
Â
